{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:33:33Z","timestamp":1786116813335,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.tjpad.2024.100005","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:27:39Z","timestamp":1736504859000},"page":"100005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Eric","family":"Siemers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Feaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalan","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Skljarevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika N.","family":"Cline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Jerecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam N.","family":"Trame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimball","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjpad.2024.100005_bib0001","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"5054","key":"10.1016\/j.tjpad.2024.100005_bib0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1750-3639.1991.tb00665.x","article-title":"Alzheimer's disease: molecular basis of structural lesions","volume":"1","author":"Masters","year":"1991","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100005_bib0004","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100005_bib0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14283\/jpad.2021.54","article-title":"The Ups and Downs of Amyloid in Alzheimer's","volume":"9","author":"Siemers","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"10.1016\/j.tjpad.2024.100005_bib0006","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100005_bib0007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100005_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.1016\/j.tjpad.2024.100005_bib0009","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.tjpad.2024.100005_bib0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100005_bib0014","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2024.100005_bib0015","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0017","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100005_bib0018","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"20","key":"10.1016\/j.tjpad.2024.100005_bib0019","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.tjpad.2024.100005_bib0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New Engl J Med"},{"issue":"S24","key":"10.1016\/j.tjpad.2024.100005_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/alz.082733","article-title":"Donanemab in early symptomatic Alzheimer's disease: efficacy and safety in TRAILBLAZER-ALZ 2, a phase 3 randomized clinical trial","volume":"19","author":"Mintun","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100005_bib0022","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100005_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.tjpad.2024.100005_bib0024","first-page":"16","article-title":"ACU193: an immunotherapeutic poised to test the amyloid \u0392 oligomer hypothesis of Alzheimer's disease","author":"Krafft","year":"2022","journal-title":"Frontiers Neurosci"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100005_bib0025","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease","volume":"24","author":"Lacor","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.tjpad.2024.100005_bib0026","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s12264-022-00985-9","article-title":"Physiological roles of \u0392-amyloid in regulating synaptic function: implications for AD pathophysiology","volume":"39","author":"Cai","year":"2023","journal-title":"Neurosci. Bull."},{"issue":"8","key":"10.1016\/j.tjpad.2024.100005_bib0027","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1038\/s41380-022-01589-5","article-title":"Bioactive human Alzheimer brain soluble A\u0392: pathophysiology and therapeutic opportunities","volume":"27","author":"Li","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100005_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14283\/jpad.2022.93","article-title":"ACU193, a monoclonal antibody that selectively binds soluble A\u00df oligomers: development rationale, phase 1 trial design, and clinical development plan","volume":"10","author":"Siemers","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"S1","key":"10.1016\/j.tjpad.2024.100005_bib0029","first-page":"S101","article-title":"ACU193-sA\u0392O complex measurement in CSF: additional analyses using a sensitive assay of target engagement for the sA\u0392O-selective antibody ACU193 in INTERCEPT-AD","volume":"10","author":"Cline","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"S1","key":"10.1016\/j.tjpad.2024.100005_bib0030","first-page":"S13","article-title":"Determination of target engagement at various doses of ACU193 in INTERCEPT-AD","volume":"10","author":"Trame","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2024.100005_bib0031","series-title":"Poster presented at Alzheimer's Association International Conference (AAIC) Philadelphia, PA","article-title":"Sabirnetug (ACU193) lowers CSF levels of synaptic biomarkers in INTERCEPT-AD phase 1 study in early AD","author":"Cline","year":"2024"}],"updated-by":[{"DOI":"10.1016\/j.tjpad.2025.100213","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:18:41Z","timestamp":1786018721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2274580724005971"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100005","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acumen Pharmaceuticals, Inc. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100005"}}